Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy
- 8 August 2006
- journal article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 32 (5) , 461-468
- https://doi.org/10.1111/j.1365-2990.2006.00734.x
Abstract
The spectrum of glioneuronal lesions underlying intractable epilepsies includes malformative pathologies like focal cortical dysplasia (FCD); and neoplastic lesions like gangliogliomas (GG) and dysembryoplastic neuroepithelial tumours (DNT). These may occur either singly or as dual lesions, having simultaneous presence of both elements. Currently, the relationship between the malformative and neoplastic glioneuronal lesions is poorly understood. Recently, CD34, a stem cell marker transiently expressed during early neurulation, has been identified in these tumours. This study was undertaken to (i) evaluate the role of CD34 as a diagnostic marker for glioneuronal lesions of epilepsy, namely, GG, DNT and FCD, and (ii) attempt to define the relationship among these lesions, using CD34 as a marker.Tissues resected from 47 patients with intractable epilepsy due to glioneuronal lesions (GG, FCD, DNT) were studied. These were evaluated for CD34 expression, using immunohistochemistry.Dysplastic or atypically differentiated neural precursors which could not be identified on routine haematoxylin and eosin (H&E) staining were highlighted by CD34 immunostaining. The pattern of immunostaining was diffuse in GGs, unlike FCDs, wherein cells were present singly or in small clusters. However, cases of DNT and control tissue were largely CD34‐immunonegative.Based on these findings, we propose a possible common origin of GG and FCD, from a bipotent precursor that undergoes abnormal glioneuronal development, while DNTs possibly have a different origin. The CD34‐immunoreactive cells represent dysplastic or undifferentiated neural precursors, which may signify a valuable marker for the diagnostic evaluation of neoplastic and/or malformative pathologies in patients with intractable epilepsy.Keywords
This publication has 21 references indexed in Scilit:
- CD34 and MAP-2 Immunohistochemistry in the Differential Diagnosis of Epilepsy-Associated Glioneuronal TumorsAdvances in Anatomic Pathology, 2004
- CD34-immunoreactive balloon cells in cortical malformationsActa Neuropathologica, 2004
- Malignant solitary fibrous tumor of the meningesVirchows Archiv, 2004
- Human CD34+cells differentiate into microglia and express recombinant therapeutic proteinProceedings of the National Academy of Sciences, 2004
- Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumorsMicroscopy Research and Technique, 1999
- Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissuesEuropean Journal of Immunology, 1995
- Gastrointestinal Stromal Tumors—Value of CD34 Antigen in their Identification and Separation from True Leiomyomas and SchwannomasThe American Journal of Surgical Pathology, 1995
- Expression of CD34 by Solitary Fibrous Tumors of the Pleura, Mediastinum, and LungThe American Journal of Surgical Pathology, 1994
- CD34 antigen: Molecular features and potential clinical applicationsThe International Journal of Cell Cloning, 1993
- The gene encoding the stem cell antigen, CD34, is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblastsInternational Immunology, 1991